| Literature DB >> 35197452 |
Qin Ning1, Di Wu2, Xiaojing Wang2, Dong Xi2, Tao Chen2, Guang Chen2, Hongwu Wang2, Huiling Lu3, Ming Wang2, Lin Zhu2, Junjian Hu2, Tingting Liu2, Ke Ma2, Meifang Han4, Xiaoping Luo5.
Abstract
The coronavirus disease 2019 (COVID-19) is a highly transmissible disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a major threat to global public health. Although COVID-19 primarily affects the respiratory system, causing severe pneumonia and acute respiratory distress syndrome in severe cases, it can also result in multiple extrapulmonary complications. The pathogenesis of extrapulmonary damage in patients with COVID-19 is probably multifactorial, involving both the direct effects of SARS-CoV-2 and the indirect mechanisms associated with the host inflammatory response. Recognition of features and pathogenesis of extrapulmonary complications has clinical implications for identifying disease progression and designing therapeutic strategies. This review provides an overview of the extrapulmonary complications of COVID-19 from immunological and pathophysiologic perspectives and focuses on the pathogenesis and potential therapeutic targets for the management of COVID-19.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35197452 PMCID： PMC8863906 DOI： 10.1038/s41392-022-00907-1
Source DB: PubMed Journal: Signal Transduct Target Ther ISSN： 2059-3635